Two Phase 3 Uveitis Trials Support Brepocitinib Steroid Sparing

Company Roivant; Priovant Therapeutics Event Type Phase 3 Topline Results (CLARITY-1 and CLARITY-2) Modality Small molecule; oral TYK2/JAK1 inhibitor Asset Brepocitinib Target TYK2; JAK1 Disease Area Noninfectious uveitis Summary Brepocitinib met the primary and multiplicity-controlled secondary endpoints in both CLARITY phase 3 studies of noninfectious…